Status:
COMPLETED
ZD6474 Phase IIa Dose Finding Multicentre Study
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Non Small Cell Lung Carcinoma
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Eligibility Criteria
Inclusion
- Provision of written informed consent.
- Life expectancy of 12 weeks or longer.
Exclusion
- Pregnancy, breast feeding or female patients wishing to become pregnant.
- Treatment with a non-approved or investigational drug within 30 days before enrolment
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00252746
Start Date
December 1 2004
End Date
January 1 2007
Last Update
August 25 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Matsuyama, Ehime, Japan
2
Research Site
Isehara, Kanagawa, Japan
3
Research Site
Okayama, Okayama-ken, Japan
4
Research Site
Sayama, Osaka, Japan